PRTN3 and COVID-19: An elevated prevalence of autoAb is often reported in patients with acute COVID-19, and the most frequent associations are described with aPL (antiphospholipid autoAb), ANA (antinuclear autoAb), RF (rheumatoid factor), and ACPA (anti-cyclic citrullinated peptide autoAb) [74].